Back to top
more

Intuitive Surgical (ISRG)

(Delayed Data from NSDQ)

$507.42 USD

507.42
849,492

+1.08 (0.21%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $507.62 +0.20 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Quest Diagnostics Boosts Health & Wellness, Acquires Provant

by Zacks Equity Research

Quest Diagnostics' (DGX) Provant Health acquisition is in line with its 'accelerate growth' strategy.

QIAGEN Introduces New RNA-seq Library Preparation Solutions

by Zacks Equity Research

QIAGEN (QGEN) adopts initiatives to boost the NGS portfolio.

Walgreens (WBA) Q4 Earnings Top Estimates, Revenues Lag

by Zacks Equity Research

Walgreens' (WBA) Retail Pharmacy USA division witnesses comparable prescription growth and benefits from a strong retail prescription market.

Intuitive Surgical (ISRG) Q3 Earnings Preview: What's Shaping Up?

by Zacks Equity Research

Intuitive Surgical (ISRG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Hold on to athenahealth (ATHN) for Now

by Zacks Equity Research

athenahealth (ATHN) likely to gain from focus on cloud-based healthcare services.

Is Intuitive Surgical (ISRG) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (ISRG) Outperforming Other Medical Stocks This Year?

Baxter & ASPEN Launch PN Tools to Boost Clinical Nutrition

by Zacks Equity Research

Baxter (BAX) and ASPEN's SmartPN lends the company a competitive edge in the MedTech space.

BioScrip Grows on CORE Plan, Reimbursement Issues Persist

by Zacks Equity Research

BioScrip (BIOS) progresses well on the back of its new multi-faceted CORE plan to improve its financial position.

Genomic Health's Test Gets Favored by New NCCN Guidelines

by Zacks Equity Research

Genomic Health (GHDX) forges ahead with the development of Oncotype DX Breast Recurrence Score test.

Accuray's (ARAY) Radixact System Used First Time in Germany

by Zacks Equity Research

Accuray's (ARAY) flagship radiotherapy systems have lucrative prospects.

Here's Why You Should Buy HealthEquity (HQY) Stock Right Now

by Zacks Equity Research

Strong presence in the HSA space and a solid guidance for fiscal 2019 make HealthEquity (HQY) a promising investment pick.

Here's Why You Should Invest in Boston Scientific Stock Now

by Zacks Equity Research

Boston Scientific (BSX) is coming up with better-than-expected earnings and revenue performances on the back of growth across all business lines and geographies.

Edwards Begins US CENTERA Study, Reintroduces Valve in Europe

by Zacks Equity Research

Edwards (EW) is recommencing commercial introduction of CENTERA valve in Europe after making certain minor modification to CENTERA's delivery system.

Here's Why You Should Invest in Genomic Health (GHDX) Now

by Zacks Equity Research

Genomic Health (GHDX) continues to see increasing private coverage for the Oncotype DX GPS test.

GNC Holdings E-Commerce Business Solid, Competition Rife

by Zacks Equity Research

GNC Holdings (GNC) continues to register strong performance in e-commerce business. A competitive landscape is a threat.

Allscripts (MDRX) & Appriss Health Collaborate to Fight SUD

by Zacks Equity Research

Allscripts' (MDRX) EHR solutions have lucrative prospects.

Express Scripts' Accredo & Akcea Tie Up to Distribute TEGSEDI

by Zacks Equity Research

Express Scripts (ESRX) likely to gain market traction through distribution of TEGSEDI.

CVS Health's Aetna Deal Imminent, PBM Selling Season Strong

by Zacks Equity Research

CVS Health (CVS) is steadily approaching the Aetna deal wrap-up. Per the company, this significant buyout might alter the whole Healthcare landscape in the United States.

Teleflex's Latest Essential Medical Buyout to Broaden Suite

by Zacks Equity Research

Teleflex (TFX) acquires Essential Medical to strengthen hold in the high-potential structural heart and endovascular aneurysm repair markets.

Here's Why You Should Buy Tandem Diabetes (TNDM) Stock Now

by Zacks Equity Research

Strength in domestic sales along with the recent launch of the t:slim X2 Insulin Pump in select international markets bode well for Tandem Diabetes (TNDM).

Here's Why You Should Invest in Henry Schein (HSIC) Stock

by Zacks Equity Research

Henry Schein's (HSIC) strategy to extend digital dentistry globally is encouraging. Recent acquisitions will strengthen its foothold in the high-potential dental market.

    Varian (VAR) & Reliance Group Tie Up to Enhance Cancer Care

    by Zacks Equity Research

    Varian (VAR) enjoys solid presence in Asia, Latin America and Africa's cancer care space.

      Europe Okays Use of Insulet's (PODD) Omnipod With Fiasp

      by Zacks Equity Research

      Fiasp's operative efficiency coupled with Insulet's (PODD) Omnipod System will provide a new option for both patients and prescribers to support their diabetes management requirements.

        Genomic Health's New Data on Oncotype DX GPS to Boost Uptake

        by Zacks Equity Research

        Genomic Health (GHDX) continues to see positive developments within the U.S. prostate cancer test business.

          Thermo Fisher (TMO) Scales a 52-Week High: What's Driving It?

          by Zacks Equity Research

          Thermo Fisher (TMO) sees strength in all end markets, categorized either by customer type or geography.